ClinicalTrials.gg

Program

Nuvastatic

Also written as “Nuvastatic™” and “Nuvastatic ™”.

Its studies are mostly in Fatigue · Breast Neoplasms · Diabetic Retinopathy · COVID-19, led by Natureceuticals Sdn Bhd.

Furthest: phase 3, since Dec 23, 20254 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Natureceuticals Sdn Bhd41 open or runningphase 3since Dec 23, 2025Sep 5, 2020Mar 31, 2027phase 3 · NCT07669519

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2020First study: phase 2 study in Diabetic RetinopathyFirst studyNCT04552600 · 100 enrolled · India
  2. Sep 6, 2020Phase 1 study in COVID-19NCT04542447 · 10 enrolled · India
  3. Dec 23, 20252 phase 3 studiesPhase 3 reachedNCT07669519, NCT07669506

Ahead

  1. Mar 31, 2027Primary completion: phase 3 study in FatigueNCT07669519

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07669519Fatigue · India3RecruitingMar 31, 2027180
NCT07669506Breast Neoplasms · India3CompletedApr 25, 2026180
NCT04542447COVID-19 · India1UNKNOWNSep 30, 202010
NCT04552600Diabetic Retinopathy · India2CompletedAug 10, 2022100

How it is read

Names in the registry

  • “Nuvastatic”, 2 entries
  • “Nuvastatic™”, 1 entry
  • “Nuvastatic ™”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.